Wall Street analysts expect that TESARO, Inc. (NASDAQ:TSRO) will post sales of $17.22 million for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for TESARO’s earnings, with estimates ranging from $10.77 million to $24.67 million. TESARO posted sales of $36.56 million in the same quarter last year, which suggests a negative year-over-year growth rate of 52.9%. The business is expected to announce its next earnings results on Thursday, August 3rd.

According to Zacks, analysts expect that TESARO will report full year sales of $17.22 million for the current financial year, with estimates ranging from $67.34 million to $196.00 million. For the next financial year, analysts forecast that the company will post sales of $428.83 million per share, with estimates ranging from $231.30 million to $554.79 million. Zacks’ sales averages are an average based on a survey of research firms that follow TESARO.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.26) by $0.29. The business had revenue of $3.10 million during the quarter, compared to the consensus estimate of $3.84 million. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. The firm’s revenue for the quarter was up 909.8% on a year-over-year basis. During the same period last year, the business posted ($2.22) EPS.

TSRO has been the subject of a number of recent research reports. Zacks Investment Research lowered shares of TESARO from a “hold” rating to a “sell” rating in a research note on Wednesday, March 22nd. Piper Jaffray Companies initiated coverage on shares of TESARO in a research note on Wednesday, April 12th. They set an “overweight” rating and a $180.00 price target for the company. Leerink Swann restated a “market perform” rating on shares of TESARO in a research note on Monday, March 20th. Robert W. Baird lowered shares of TESARO from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $127.00 to $182.00 in a research note on Monday, February 27th. Finally, Jefferies Group LLC boosted their price target on shares of TESARO from $80.00 to $124.00 and gave the company a “hold” rating in a research note on Monday, March 27th. Nine research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $173.68.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate TESARO, Inc. (TSRO) Will Announce Quarterly Sales of $17.22 Million” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/06/23/analysts-anticipate-tesaro-inc-tsro-will-announce-quarterly-sales-of-17-22-million.html.

In related news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $153.02, for a total transaction of $126,853.58. Following the completion of the transaction, the senior vice president now owns 6,522 shares in the company, valued at $997,996.44. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Edward C. English sold 8,500 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. Vident Investment Advisory LLC bought a new position in TESARO during the first quarter valued at $351,000. Meeder Asset Management Inc. bought a new position in TESARO during the first quarter valued at $177,000. Soros Fund Management LLC bought a new position in TESARO during the first quarter valued at $262,000. Stephens Inc. AR raised its position in TESARO by 11.0% in the first quarter. Stephens Inc. AR now owns 1,759 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 175 shares during the last quarter. Finally, First Citizens Bank & Trust Co. bought a new position in TESARO during the first quarter valued at $288,000.

TESARO (TSRO) traded up 1.2667% on Friday, reaching $151.6671. 519,149 shares of the company were exchanged. The company’s 50-day moving average price is $145.51 and its 200-day moving average price is $151.49. TESARO has a 12-month low of $36.71 and a 12-month high of $192.94. The stock’s market capitalization is $8.17 billion.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.